Dr. Lal PathLabs reported a 15.2% drop in Q4 FY26 net profit to ₹131.3 crore, despite revenue rising 16.6% to ₹702.7 crore on strong demand. EBITDA grew 11%, but margins slipped to 26.6%. The company recommended a ₹4 per share dividend, while its stock declined slightly after the results.